Opinion|Videos|July 24, 2024
Examining the Evolving 3L Treatment Landscape for mCRC
Colorectal cancer specialists examine treatment sequencing strategies for third-line and subsequent therapy settings, while also evaluating regorafenib's efficacy and real-world outcomes.
Advertisement
Episodes in this series
- Briefly Given the latest approvals, is there a continued role for regorafenib in mCRC and how do real-world outcomes support its use? (Yisilamu P, et al. ASCO 2024. Abstract e15562)
- Dr Marshall to Panel:Let’s explore sequencing strategies for CRC in the 3L setting and beyond. Discuss how new data and other considerations impact treatment selection and sequencing.
- Dr Marshall to Panel: How would you describe your current approach to treatment sequencing?
- Dr Benson: How do you approach treating patients with fruquintinib from FRESCO and FRESCO-2 studies according to prior treatment sequence? (
Bekaii-Saab T, et al. ASCO 2024. Abstract 3579 .)- Impact of prior bevacizumab
- Dr Fakih:Please comment on recently presented data from the SUNLIGHT study and the implications on your treatment sequencing:
- Impact of prior fluoropyrimidine (
Fakih, et al. ASCO GI 2024. Abstract 114 ) - Impact of prior bevacizumab
- Impact of prior fluoropyrimidine (
- Dr Cohen: Regorafenib and/or TAS-102 sequencing (
Signorelli C, et al. ASCO 2024. Abstract e15553)
Advertisement
Related to this article
The FDA approval of daraxonrasib was based on data from the phase 3 RASolute 302 trial in previously treated metastatic pancreatic ductal adenocarcinoma.
Ivonescimab plus chemotherapy significantly improved overall survival vs durvalumab plus chemotherapy in advanced biliary tract cancer.
The FDA has approved zanidatamab plus chemotherapy with/without tislelizumab in frontline HER2-positive GEA based on data from HERIZON-GEA-01.
The oral pan-RAS molecular glue ERAS-0015 has received FDA fast track designation for the management of metastatic pancreatic adenocarcinoma.
The FDA set a target action date of February 2027 for the dostarlimab-gxly sBLA in dMMR/MSI-H locally advanced rectal cancer.
The top 5 OncLive TV videos of the week cover insights in ovarian cancer, breast cancer, head and neck cancer, pancreatic cancer, and follicular lymphoma.
Neeta Somaiah, MD, discusses the significance of the Peak study and what an approval of bezuclastinib plus sunitinib would mean for GIST.
Updated ASCO Living Guideline recommendations expand frontline therapy for HER2-positive gastroesophageal cancer to include zanidatamab-based regimens.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daraxonrasib for Metastatic Pancreatic Ductal Adenocarcinoma
2
Dr Reiss Binder on the FDA Approval of Daraxonrasib for Metastatic PDAC
3
ASCO Issues Warning Regarding Ifosfamide Shortage for Cancer Care
4
Dr Ayanambakkam on the Safety of Darlifarnib Plus Cabozantinib in RCC KD
5